Patnaik Rupali, Azim Afzal, Mishra Prabhaker
Department of Critical Care Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Biostatistics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):458-464. doi: 10.4103/joacp.JOACP_388_19. Epub 2021 Jan 18.
Sepsis is a life-threatening condition with dysregulated host response to infection. It is a major determinant of mortality in the intensive care unit (ICU). Procalcitonin (PCT) is widely investigated for prognosis in patients with sepsis. Most of the studies have cited that elevated PCT concentrations and PCT non-clearance are associated with poor outcomes in patients with sepsis and some studies have cited as having no additional benefit. Most of the studies have evaluated single PCT measurement and correlated with prognosis and outcome in septic patients. Limited literature is there about serial PCT levels and its impact on the outcome of patients with sepsis. We searched literature through PubMed, Embase, Web of Knowledge, and the Cochrane Library from 2007 to 2017 and present a systematic review and meta-analysis of studies evaluating the utility of serial measurement of PCT for prognosis in critically ill patients. Articles that assessed PCT non-clearance as a marker of mortality data were included. The primary objective of this meta-analysis was to pool the results of all the available studies on serial PCT non-clearance as a mortality predictor and formulate overall area under receiver operating curve (AUROC). To find out the overall proportion of mortality in PCT non-clearance was our secondary objective. To detect the mortality using PCT non-clearance, ROC curve analysis was done. Area under curve (AUC) of the studies was varying between 0.52 and 0.86. Overall AUC was observed 0.711 (95% confidence interval (CI): 0.662-0.760) under fixed effect model and 0.708 (95% CI: 0.648-0.769) under random effect model. There was moderate variation among the studies, i.e., I 50.80% (95% CI: 0.00-80.42%). The overall proportion of mortality was 37.54% with much heterogeneity (I 88.24%) among the studies. PCT non-clearance is a fair predictor of mortality. Further studies are needed to define optimal cut off point for PCT non-clearance in ICU patients with sepsis.
脓毒症是一种因宿主对感染反应失调而危及生命的病症。它是重症监护病房(ICU)死亡率的主要决定因素。降钙素原(PCT)在脓毒症患者预后方面得到了广泛研究。大多数研究表明,脓毒症患者PCT浓度升高及PCT清除不佳与不良预后相关,而一些研究则认为其并无额外益处。大多数研究评估的是单次PCT测量,并将其与脓毒症患者的预后和结局相关联。关于连续PCT水平及其对脓毒症患者结局影响的文献有限。我们通过PubMed、Embase、Web of Knowledge和Cochrane图书馆检索了2007年至2017年的文献,并对评估连续测量PCT对危重症患者预后效用的研究进行了系统评价和荟萃分析。纳入了将PCT清除不佳评估为死亡率数据标志物的文章。本荟萃分析的主要目的是汇总所有关于连续PCT清除不佳作为死亡率预测指标的现有研究结果,并制定总体受试者工作特征曲线下面积(AUROC)。找出PCT清除不佳时的总体死亡率比例是我们的次要目标。为了利用PCT清除不佳检测死亡率,进行了ROC曲线分析。各研究的曲线下面积(AUC)在0.52至0.86之间变化。在固定效应模型下,总体AUC为0.711(95%置信区间(CI):0.662 - 0.760),在随机效应模型下为0.708(95%CI:0.648 - 0.769)。各研究之间存在中度异质性,即I²为50.80%(95%CI:0.00 - 80.42%)。总体死亡率比例为37.54%,各研究之间存在很大异质性(I²为88.24%)。PCT清除不佳是死亡率的一个合理预测指标。需要进一步研究来确定脓毒症ICU患者PCT清除不佳的最佳截断点。